Altimmune to present clinical data from pemvidutide at upcoming easl international liver congress™ 2024

Gaithersburg, md., may 29, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (masld) will be presented at the easl international liver congress™ 2024 in milan, italy. pemvidutide is a novel, investigational, peptide-based glp-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (mash).
ALT Ratings Summary
ALT Quant Ranking